Literature DB >> 24123114

Hepatitis C virus clearance correlates with HLA-DR expression on proliferating CD8+ T cells in immune-primed chimpanzees.

Iryna Zubkova1, Hongying Duan, Frances Wells, Howard Mostowski, Esther Chang, Kathleen Pirollo, Kris Krawczynski, Robert Lanford, Marian Major.   

Abstract

UNLABELLED: Vaccination of chimpanzees against hepatitis C virus (HCV) using T-cell-based vaccines targeting nonstructural proteins has not resulted in the same levels of control and clearance as those seen in animals reexposed after HCV clearance. We hypothesized that the outcome of infection depends on the different subtypes of activated T cells. We used multicolor flow cytometry to evaluate activation (CD38+/HLA-DR+) and proliferation (Ki67+/Bcl-2-low) profiles of CD4+ and CD8+ T cells in peripheral blood before and after challenge in chimpanzees vaccinated using DNA/adenovirus, mock-vaccinated, and chimpanzees that had spontaneously cleared infection (rechallenged). The frequencies of activated or proliferating CD8+ T cells peaked at 2 weeks postchallenge in the vaccinated and rechallenged animals, coinciding with reductions in viral titers. However, the magnitude of the responses did not correlate with outcome or sustained control of viral replication. In contrast, proliferation of the CD8+ T cells coexpressing HLA-DR either with or without CD38 expression was significantly higher at challenge in animals that rapidly cleared HCV and remained so throughout the follow-up period.
CONCLUSION: Our data suggest that the appearance of proliferating HLA-DR+/CD8+ T cells can be used as a predictor of a successfully primed memory immune response against HCV and as a marker of effective vaccination in clinical trials.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24123114      PMCID: PMC4079472          DOI: 10.1002/hep.26747

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Bad time for Bonzo? Experimental models of hepatitis C virus infection, replication, and pathogenesis.

Authors:  A Grakoui; H L Hanson; C M Rice
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

Review 2.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

3.  The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells.

Authors:  E Endl; I Kausch; M Baack; R Knippers; J Gerdes; T Scholzen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

4.  Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses.

Authors:  J M McNally; C C Zarozinski; M Y Lin; M A Brehm; H D Chen; R M Welsh
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection.

Authors:  S E Bassett; B Guerra; K Brasky; E Miskovsky; M Houghton; G R Klimpel; R E Lanford
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

6.  Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge.

Authors:  Marian E Major; Kathleen Mihalik; Montserrat Puig; Barbara Rehermann; Michelina Nascimbeni; Charles M Rice; Stephen M Feinstone
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

8.  Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities.

Authors:  Rajia Bahri; Annalena Bollinger; Thomas Bollinger; Zane Orinska; Silvia Bulfone-Paus
Journal:  PLoS One       Date:  2012-09-17       Impact factor: 3.240

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Determinants of viral clearance and persistence during acute hepatitis C virus infection.

Authors:  R Thimme; D Oldach; K M Chang; C Steiger; S C Ray; F V Chisari
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

View more
  14 in total

1.  Hepatic immunopathology during occult hepacivirus re-infection.

Authors:  Cordelia Manickam; Amanda J Martinot; Rhianna A Jones; Valerie Varner; R Keith Reeves
Journal:  Virology       Date:  2017-09-13       Impact factor: 3.616

Review 2.  Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Authors:  Babs E Verstrepen; André Boonstra; Gerrit Koopman
Journal:  World J Hepatol       Date:  2015-01-27

Review 3.  Will there be a vaccine to prevent HCV infection?

Authors:  Jonathan R Honegger; Yan Zhou; Christopher M Walker
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

4.  Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.

Authors:  Xuyong Wei; Wentao Xie; Weiwei Yin; Mengfan Yang; Abdul Rehman Khan; Renyi Su; Wenzhi Shu; Binhua Pan; Guanghan Fan; Kun Wang; Fan Yang; Di Lu; Changbiao Li; Linhui Pan; Beini Cen; Haiyang Xie; Li Zhuang; Shusen Zheng; Xun Zeng; Wei Chen; Xiao Xu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 5.  Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

Authors:  Heidi Barth
Journal:  World J Hepatol       Date:  2015-04-18

Review 6.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

7.  Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.

Authors:  Wendy G Tan; Iryna Zubkova; Alla Kachko; Frances Wells; Heiko Adler; Gerd Sutter; Marian E Major
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240

Review 8.  Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.

Authors:  Justin R Bailey; Eleanor Barnes; Andrea L Cox
Journal:  Gastroenterology       Date:  2018-09-27       Impact factor: 22.682

9.  During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.

Authors:  Alessandra Ruggiero; Ward De Spiegelaere; Alessandro Cozzi-Lepri; Maja Kiselinova; Georgios Pollakis; Apostolos Beloukas; Linos Vandekerckhove; Matthew Strain; Douglas Richman; Andrew Phillips; Anna Maria Geretti
Journal:  EBioMedicine       Date:  2015-07-21       Impact factor: 8.143

Review 10.  Challenges and Promise of a Hepatitis C Virus Vaccine.

Authors:  Andrea L Cox
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.